Member Sign In

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

Thermo Fisher Beats, Ups Guidance

You have chosen to follow this author. You will receive an email notification when this author publishes a new article. Click submit to continue.

You are alredy following the Author

The Author could not be added at this time, please try again later. If problem persists, please contact Zacks Customer support.

Please Login

Thermo Fisher Scientific (TMO - Analyst Report) reported an EPS of 64 cents in the first quarter of fiscal 2011 compared to 56 cents in the year-ago period. However, after adjusting for certain one-time items, the EPS was 92 cents, surpassing the Zacks Consensus Estimate of 88 cents and earnings of 82 cents in the first quarter of 2010 by 12%.

The company’s revenue of $2.72 billion during the quarter marginally beat the Zacks Consensus Estimate of $2.71 billion and was 4% higher than $2.63 billion in the first quarter of fiscal 2010. Acquisitions had a positive impact of 2% on revenues with 1% favorable effect from currency movement.

The company exited the quarter with cash and cash equivalents of $2.8 billion compared with $917.1 million at the end of December 2010. A strong cash balance helps the company pursue suitable acquisitions or reward its shareholders through share buybacks.

Thermo Fisher spent $538 million to buy back 9.6 million shares and was left with $700 million of authorization at quarter end. The company also sold two laboratory-testing services businesses – Athena Diagnostics and Lancaster Laboratories resulting in total proceeds of $940 million.

Guidance

Based on a strong quarter, Thermo Fisher raised its guidance for fiscal 2011. The company expects revenue in the range of $11.52-$11.62 billion (previous guidance of $11.33-$11.45 billion) and representing growth of 9%-10%.

Moreover, the adjusted EPS was raised by 5 cents to $4.05-$4.15, representing a 17%-20% growth. While the Zacks Consensus Estimate of $4.06 is at the lower end of the guidance, the revenue estimate of $11.44 billion is much lower than the company’s outlook. This guidance includes the acquisition of Dionex Corporation , which is expected to close in mid-May.

Recommendation

A gradual improvement in the economic scenario along with the focus on emerging markets should drive Thermo Fisher’s top line in the forthcoming period. The company is increasing investment in emerging markets with plans to build new manufacturing facility in China to serve local life sciences customers.

Moreover, strong cash position should assist the company in making suitable acquisitions, reduce debt burden or repurchase shares. However, any kind of economic turbulence could negatively impact the company’s sales based on financial constraints and customers deferring their purchase.

We are currently Neutral on the stock, which also corresponds to the Zacks #3 Rank (Hold) in the short-term.

Top Zacks Features

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

Zacks Research is Reported On:

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.

Visit performance for information about the performance numbers displayed above.